Cytokinetics Announces Second Annual Communications Fellowship Program Call for Proposals
September 25 2019 - 7:30AM
Cytokinetics, Incorporated (Nasdaq: CYTK) today announced a call
for proposals for the second annual Cytokinetics Communications
Fellowship Grant program. The Fellowship program provides a total
of $100,000 in grants to five selected patient advocacy
organization serving the amyotrophic lateral sclerosis (ALS), heart
failure, hypertrophic cardiomyopathy (HCM), or spinal muscular
atrophy (SMA) communities, and is intended to support increased
capacity in communications, awareness building and community
engagement.
“After the success of our pilot program last
year, we look forward to selecting patient advocacy organizations
which may benefit from added support to amplify their messages,
connect with more advocates, and expand their reach in the
communities they serve,” said Diane Weiser, Cytokinetics’ Vice
President of Corporate Communications and Investor Relations. “As a
company who puts patients first, we are committed to elevating and
promoting patient and caregiver voices as we continue to make
progress towards advancing potential new medicines for patients in
need.”
The Communications Fellowship program is awarded
annually to patient advocacy organizations serving patients with
ALS, heart failure, HCM or SMA to provide funding in support of
communications, awareness and outreach. The goal of the Fellowship
is to assist patient advocacy organizations by increasing resources
in order to better support patient communities and bring increased
awareness to the disease in the communities they serve.
Eligible organizations must have nonprofit
organization status in the United States, and serve the
cardiovascular or neuromuscular patient communities in ALS, heart
failure, HCM or SMA. The deadline to apply is November 15, 2019 and
the grant recipients will be announced in January 2020.
Organizations applying for the grant are
required to submit a proposal outlining what activities the
Fellowship program will support and the potential impact of the
additional funding. Recipients are responsible for providing an
outcomes report to Cytokinetics to measure impact at the end of the
funding period. For more information on application criteria, and
instructions for how to apply, visit
www.cytokinetics.com/fellowship.
About Cytokinetics
Cytokinetics is a late-stage biopharmaceutical
company focused on discovering, developing and commercializing
first-in-class muscle activators and best-in-class muscle
inhibitors as potential treatments for debilitating diseases in
which muscle performance is compromised and/or declining. As a
leader in muscle biology and the mechanics of muscle performance,
the company is developing small molecule drug candidates
specifically engineered to impact muscle function and
contractility. Cytokinetics is collaborating with Amgen Inc.
(Amgen) to develop omecamtiv mecarbil, a novel cardiac muscle
activator. Omecamtiv mecarbil is the subject of an international
clinical trials program in patients with heart failure including
GALACTIC-HF and METEORIC-HF. Amgen holds an exclusive worldwide
license to develop and commercialize omecamtiv mecarbil with a
sublicense held by Servier for commercialization in Europe and
certain other countries. Cytokinetics is collaborating with
Astellas Pharma Inc. (Astellas) to develop reldesemtiv, a fast
skeletal muscle troponin activator (FSTA). Astellas holds an
exclusive worldwide license to develop and commercialize
reldesemtiv. Licenses held by Amgen and Astellas are subject to
specified co-development and co-commercialization rights of
Cytokinetics. Cytokinetics is also developing CK-274, a novel
cardiac myosin inhibitor that company scientists discovered
independent of its collaborations, for the potential treatment of
hypertrophic cardiomyopathies. Cytokinetics continues its over
20-year history of pioneering innovation in muscle biology and
related pharmacology focused to diseases of muscle dysfunction and
conditions of muscle weakness.
For additional information
about Cytokinetics, visit www.cytokinetics.com and follow
us on Twitter, LinkedIn, Facebook and YouTube.
Forward-Looking Statements
This press release contains forward-looking
statements for purposes of the Private Securities Litigation Reform
Act of 1995 (the “Act”). Cytokinetics disclaims any intent or
obligation to update these forward-looking statements and claims
the protection of the Act’s Safe Harbor for forward-looking
statements. Examples of such statements include, but are not
limited to, statements relating to Cytokinetics’ and its partners’
research and development activities of Cytokinetics’ product
candidates. Such statements are based on management’s current
expectations, but actual results may differ materially due to
various risks and uncertainties, including, but not limited to the
risks related to Cytokinetics’ business outlines in Cytokinetics’
filings with the Securities and Exchange Commission.
Forward-looking statements are not guarantees of future
performance, and Cytokinetics’ actual results of operations,
financial condition and liquidity, and the development of the
industry in which it operates, may differ materially from the
forward-looking statements contained in this press release. Any
forward-looking statements that Cytokinetics makes in this press
release speak only as of the date of this press release.
Cytokinetics assumes no obligation to update its forward-looking
statements whether as a result of new information, future events or
otherwise, after the date of this press release.
Contact:CytokineticsDiane WeiserVice President,
Corporate Communications, Investor Relations(415) 290-7757
Cytokinetics (NASDAQ:CYTK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cytokinetics (NASDAQ:CYTK)
Historical Stock Chart
From Apr 2023 to Apr 2024